SecBot SecBot
PRESS-RELEASE ·Filed Aug 13, 2026

BBIO

BridgeBio Pharma, Inc.
BEARISH
Impact 5/10
Horizondays Processed3mo ago WireGlobeNewswire
Press release · Offering
Actionable Insight ▼ Bearish

The secondary offering creates near-term overhang as KKR exits a meaningful position. However, the company's strong Q2 revenue growth ($243.7M, more than doubling YoY) and upcoming PDUFA catalysts (BBP-418 Nov 27, 2026; encaleret May 8, 2027) provide fundamental support. Traders should watch for the final pricing and any accelerated bookbuilding that could signal weaker demand. The offering's completion may create a buying opportunity if the stock dips excessively given the upcoming catalysts.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$79.86
T+0 close · Aug 13, 2026 · via day close
Latest settled
−2.91%
T+60 · $77.54
Vs SPY
−0.10%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $79.86entry
  2. T+1 · 3mo ago +0.04%α +0.51% · $79.89
  3. T+5 · 3mo ago +2.05%α +3.42% · $81.50
  4. T+20 · 2mo ago −9.37%α −7.38% · $72.38
  5. T+60 · 7d ago −2.91%α −0.10% · $77.54
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio announced a secondary offering of 5,000,000 shares by KKR Genetic Disorder L.P., with the company receiving no proceeds. This overhang from a large existing holder selling into a $16.4B market cap creates moderate dilution pressure, though the company's strong Q2 revenue growth and upcoming PDUFA catalysts partially offset the sentiment. The offering follows a $1B preferred equity financing and positive Q2 results, suggesting KKR is taking partial profits rather than signaling distress.

Key Facts

  • KKR Genetic Disorder L.P. is selling 5,000,000 shares of BridgeBio common stock in a secondary public offering
  • BridgeBio will not receive any proceeds from the offering
  • William Blair, Goldman Sachs & Co. LLC and KKR are joint book-running managers
  • The offering is being made under an automatic shelf registration statement (Form S-3ASR) filed July 24, 2026
  • BridgeBio reported Q2 2026 revenue of $243.7M (more than doubling YoY) with $222.4M in Attruby sales
  • Key upcoming catalysts: BBP-418 PDUFA Nov 27, 2026 and encaleret PDUFA May 8, 2027
  • A $1B preferred equity financing was completed post-Q2 2026

Financial Impact

5,000,000 shares represent approximately 2.5-3% of outstanding shares (based on $16.4B market cap and ~$60 stock price), creating moderate near-term selling pressure

dilutionstock priceshare count

Risk Factors

  • Secondary offering overhang could pressure stock in the near term as KKR sells 5M shares
  • Company still operating at a net loss ($152.2M in Q2 2026) despite strong revenue growth
  • Dependence on Attruby sales for near-term revenue with upcoming PDUFA catalysts creating binary risk

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3345025

Track record

38 reports on BBIO

Performance horizon

9 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $77.36 −1.04% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $77.36 −0.73% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $77.36 +3.22% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $77.36 +9.23% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $77.36 +13.56% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $77.36 +22.21% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $77.36 +15.53% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Tue (< 1m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026